Embed Size (px)
Citation preview
ALOPECIAgen
Predisposition to Androgenetic Hair Loss
EN
®
Discover Yourself
®
Results and Interpretation
based on the risk group and the gender of the patient, ALOPECIAgen allows determining whether a mi-noxidil and/or finasteride treatment will be beneficial.
Provided nutrigenetic and lifestyle recommendations in the ALOPE-CIAgen contribute to the prevention of androgenetic alopecia.
Additional Information
Since ALOPECIAgen is a genetic analysis, it needs to be carried out only once in a lifetime.
Required sample material is either a blood sample or a saliva sample.
Facts
Hair loss usually sets in between the ages of 20 and 30 years. First symp-toms are thinning and loss of the hair in the parietal, frontal and tem-poral areas.
In case of an androgenetic alopecia, hair loss is irreversible.
Who and when should be tested?
Men and women between the ages of 20 and 30 years with family history of androgenetic alopecia, preferably before the onset of any symptoms.
Why ALOPECIAgen?
Easy to carry out and innovative
Prevention is the only possibility to delay or to stop the premature deve-lopment of androgenetic alopecia.
ALOPECIAgen demonstrates a dis-tinction of three different alopecia risk groups.
LR100QK014A_PM_GE_FL_003_041113_EN_DP_V02
w w w . l a b o . l u • [email protected]. +352-780 290 -1 • Fax +352-788 89438, rue Hiehl • Z.A.C. Laangwiss • L-6131 Junglinster
